We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Feather Safety Razor

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

J&J’s Monarch Becomes First Multispecialty Surgical Robot for Use in Both Bronchoscopy and Urology

By HospiMedica International staff writers
Posted on 04 May 2022
Print article
Image: MONARCH Endoscopic Robotic Platform (Photo courtesy of Auris Health)
Image: MONARCH Endoscopic Robotic Platform (Photo courtesy of Auris Health)

Ureteroscopic procedures are the most common surgical stone procedures globally but become increasingly challenging as stone size increases. Percutaneous nephrolithotomy (PCNL) procedures have demonstrated superior stone clearance for patients with larger kidney stones, but still represent a small portion of the total stone procedures conducted due to numerous barriers. Now, a new robotic platform that supports both ureteroscopic and PCNL procedures overcomes many of these obstacles by using unique and minimally invasive technology.

The MONARCH Platform from Auris Health, Inc., a subsidiary of Ethicon, Inc., a Johnson & Johnson MedTech (New Brunswick, NJ, USA) company, is designed to enable urologists to reach and visualize areas within the kidney with precision and control. Since 2018, physicians have used MONARCH to perform robotically assisted bronchoscopy procedures and reach small, hard-to-reach peripheral lung nodules at an earlier stage and with greater precision than ever before. MONARCH Platform has now received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for endourological procedures, making it the first and only multispecialty, flexible robotic solution for use in both bronchoscopy and urology.

“This latest FDA 510(k) clearance for MONARCH delivers on our vision to extend the robotic platform’s capabilities across multiple specialties, enabling hospital systems to target two disease states using one device,” said Vladimir Makatsaria, Company Group Chairman, Ethicon. “At Ethicon, we’re committed to driving meaningful innovation that elevates the standard of care for patients and delivers improved solutions that address important clinical challenges for our customers.”

“With this FDA clearance, MONARCH is poised to aid physicians in their goals of reducing overall retreatment and complication rates,” said Jaime Landman, MD, Chairman & Professor, Department of Urology at University of California Irvine. “Furthermore, as physicians strive to elevate the standard of care and improve outcomes, MONARCH supports them in their primary goal of rendering patients stone free in a single procedure.”

“MONARCH reduces the complexity of gaining high-quality percutaneous access and aids stone clearance efficiency through simultaneous fragmentation and suctioning of stones with robotic assistance,” said Mihir Desai, MD, Professor of Clinical Urology, University of Southern California. “With this platform, many urologists may be willing to expand their practice to include percutaneous access and PCNL procedures, thereby increasing patient access to more effective treatments closer to home.”

Related Links:
Johnson & Johnson MedTech 


Print article

Channels

Critical Care

view channel
Image: EsoGuard has demonstrated over 90% specificity and 90% sensitivity in identifying Barrett’s Esophagus (Photo courtesy of Lucid Diagnostics)

Biomarker Based Non-Endoscopic Technology Identifies Risk for Esophageal Cancer

Barrett's esophagus (BE) is the benign and treatable precursor condition to esophageal adenocarcinomas (EAC) which is usually diagnosed at an advanced stage and is difficult to treat. Finding BE, a sign... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.